Drugs / PEGylated uricase
PEGylated uricase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05226013 | Dec 2021 → Dec 2022 | — | The Affiliated Hospital of Qingdao University | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEGylated uricase | “tolerability, pharmacokinetics, pharmacodynamics (PK/PD), and immunogenicity of PEGylated uricase (PEG-UOX) in healthy adults and patients with hyperuricaemia.” PMID 40557749 ↗ Jun 2025 |
| Known as | PEG uric oxidase | “single administration of PEG uric oxidase for injection in healthy adults and hyperuricemia volunteers.” NCT05226013 ↗ |
| Known as | PEG-UOX | “tolerability, pharmacokinetics, pharmacodynamics (PK/PD), and immunogenicity of PEGylated uricase (PEG-UOX) in healthy adults and patients with hyperuricaemia.” PMID 40557749 ↗ Jun 2025 |
| Known as | PEGylated urate oxidase | “a new intravenous PEGylated urate oxidase produced by Xiuzheng Bio-Medicine Research Institute Co., Ltd.” PMID 38164417 ↗ Dec 2023 |
| Known as | PEGylated Urate Oxidase for Injection | “PEGylated Urate Oxidase for Injection，specification:5mg，Single dose ascending.” NCT05226013 ↗ |
| Known as | Pegylated Uric Acid Oxidase for Injection | “Pegylated Uric Acid Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers” NCT05226013 ↗ |
| Known as | Polyglycol lated urate oxidase for injection | “Polyglycol lated urate oxidase for injection” NCT05226013 ↗ |
| Modality | Protein / enzyme biologic | “The enzyme urate oxidase can metabolize urate to allantoin” PMID 38164417 ↗ Dec 2023 |
| Route | Intravenous | “Participants received a single intravenous dose” PMID 40557749 ↗ Jun 2025 |